Pharsight

1. Abilify patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7550445 (Pediatric)	OTSUKA	Aripiprazole complex formulation and method	Jan, 2025 (5 hours ago)
US7115587 (Pediatric)	OTSUKA	Aripiprazole complex formulation and method	Jan, 2025 (5 hours ago)

Drug Exclusivity	Drug Exclusivity Expiration
Pediatric Exclusivity(PED)	Aug 27, 2011
New Indication(I-616)	Nov 19, 2012
New Indication(I-633)	Feb 16, 2014
M(M-137)	Jun 09, 2017
New Indication(I-700)	Dec 12, 2017
Orphan Drug Exclusivity(ODE)	Dec 12, 2021
Orphan Drug Exclusivity(ODE-80)	Dec 12, 2021

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 20 September, 2006

Treatment: NA

Dosage: INJECTABLE

Strength	Dosage	Availability
9.75MG/1.3ML (7.5MG/ML)	INJECTABLE	Discontinued

ABILIFY family patents

2. Adrenaclick patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166344	IMPAX	Injection needle assembly	Jan, 2025 (5 hours ago)
US10166334	IMPAX	Medicine injection apparatuses	Jan, 2025 (5 hours ago)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 25 November, 2009

Treatment: NA

Dosage: INJECTABLE

Strength	Dosage	Availability
EQ 0.3MG/DELIVERY	INJECTABLE	Prescription
EQ 0.15MG/DELIVERY	INJECTABLE	Prescription

ADRENACLICK family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Advair Hfa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444	GLAXO GRP LTD	Actuation indicator for a dispensing device	Jan, 2025 (17 days ago)

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 08 June, 2006

Treatment: NA

Dosage: AEROSOL, METERED

Strength	Dosage	Availability
0.115MG/INH;EQ 0.021MG BASE/INH	AEROSOL, METERED	Prescription

ADVAIR HFA family patents

4. Ampyra patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8663685	MERZ PHARMS	Sustained release aminopyridine composition	Jan, 2025 (3 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jan 22, 2015
Orphan Drug Exclusivity(ODE)	Jan 22, 2017

Drugs and Companies using DALFAMPRIDINE ingredient

NCE-1 date: 22 January, 2014

Market Authorisation Date: 22 January, 2010

Treatment: Improvement of walking in patients with multiple sclerosis (ms)

Dosage: TABLET, EXTENDED RELEASE

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg	22 Jan, 2014	8	23 Jan, 2017	26 May, 2027	Eligible

Strength	Dosage	Availability
10MG	TABLET, EXTENDED RELEASE	Prescription

AMPYRA family patents

5. Auvi-q patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690	KALEO INC	Devices, systems and methods for medicament delivery	Jan, 2025 (6 days ago)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 17 November, 2017

Treatment: NA

Dosage: SOLUTION

Strength	Dosage	Availability
EQ 0.3MG/DELIVERY	SOLUTION	Prescription
EQ 0.15MG/DELIVERY	SOLUTION	Prescription
EQ 0.1MG/DELIVERY	SOLUTION	Prescription

AUVI-Q family patents

6. Bepreve patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784789	BAUSCH AND LOMB INC	Aqueous liquid preparations and light-stabilized aqueous liquid preparations	Jan, 2025 (8 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Sep 08, 2014

Drugs and Companies using BEPOTASTINE BESILATE ingredient

NCE-1 date: 08 September, 2013

Market Authorisation Date: 08 September, 2009

Treatment: NA

Dosage: SOLUTION/DROPS

Strength	Dosage	Availability
1.5%	SOLUTION/DROPS	Prescription

BEPREVE family patents

7. Duvyzat patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7329689	ITALFARMACO SPA	Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester	Jan, 2025 (6 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Mar 21, 2029
Orphan Drug Exclusivity(ODE-473)	Mar 21, 2031

Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient

NCE-1 date: 21 March, 2028

Market Authorisation Date: 21 March, 2024

Treatment: NA

Dosage: SUSPENSION

Strength	Dosage	Availability
EQ 8.86MG BASE/ML	SUSPENSION	Prescription

DUVYZAT family patents

8. Edarbi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920	AZURITY	Benzimidazole derivative and use as a II receptor antagonist	Jan, 2025 (14 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 25 February, 2011

Treatment: Treatment of hypertension

Dosage: TABLET

Strength	Dosage	Availability
EQ 80MG MEDOXOMIL	TABLET	Prescription
EQ 40MG MEDOXOMIL	TABLET	Prescription

EDARBI family patents

9. Edarbyclor patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920	AZURITY	Benzimidazole derivative and use as a II receptor antagonist	Jan, 2025 (14 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Combination(NC)	Dec 20, 2014
New Chemical Entity Exclusivity(NCE)	Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET

Strength	Dosage	Availability
EQ 40MG MEDOXOMIL;25MG	TABLET	Prescription
EQ 40MG MEDOXOMIL;12.5MG	TABLET	Prescription

EDARBYCLOR family patents

10. Entresto patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659	NOVARTIS PHARMS CORP	Methods of treatment and pharmaceutical composition	Jan, 2025 (6 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Jul 07, 2020
New Patient Population(NPP)	Oct 01, 2022
Pediatric Exclusivity(PED)	Apr 01, 2023
M(M-82)	Feb 16, 2024

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: NA

Dosage: TABLET

Strength	Dosage	Availability
24MG;26MG	TABLET	Prescription
97MG;103MG	TABLET	Prescription
49MG;51MG	TABLET	Prescription

ENTRESTO family patents

11. Entresto Sprinkle patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659	NOVARTIS	Methods of treatment and pharmaceutical composition	Jan, 2025 (6 days ago)

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Market Authorisation Date: 12 April, 2024

Treatment: NA

Dosage: CAPSULE, PELLETS

Strength	Dosage	Availability
15MG;16MG	CAPSULE, PELLETS	Prescription
6MG;6MG	CAPSULE, PELLETS	Prescription

ENTRESTO SPRINKLE family patents

12. Evzio patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690	KALEO INC	Devices, systems and methods for medicament delivery	Jan, 2025 (6 days ago)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION

Strength	Dosage	Availability
0.4MG/0.4ML (0.4MG/0.4ML)	SOLUTION	Discontinued

EVZIO family patents

13. Evzio (autoinjector) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690	KALEO INC	Devices, systems and methods for medicament delivery	Jan, 2025 (6 days ago)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION

Strength	Dosage	Availability
2MG/0.4ML (2MG/0.4ML)	SOLUTION	Discontinued

EVZIO (AUTOINJECTOR) family patents

14. Fentora patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8092832	CEPHALON	Generally linear effervescent oral fentanyl dosage form and methods of administering	Dec, 2024 (22 days ago)
US8119158	CEPHALON	Effervescent oral fentanyl dosage form and methods of administering fentanyl	Dec, 2024 (22 days ago)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 25 September, 2006

Treatment: NA

Dosage: TABLET

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.6 mg and 0.8 mg	13 Nov, 2007	1	07 Jan, 2011	26 Mar, 2019	Extinguished Deferred

Strength	Dosage	Availability
EQ 0.2MG BASE	TABLET	Discontinued
EQ 0.8MG BASE	TABLET	Discontinued
EQ 0.4MG BASE	TABLET	Discontinued
EQ 0.1MG BASE	TABLET	Discontinued
EQ 0.6MG BASE	TABLET	Discontinued

FENTORA family patents

15. Flovent Hfa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444	GLAXO GRP LTD	Actuation indicator for a dispensing device	Jan, 2025 (17 days ago)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 14 May, 2004

Treatment: NA

Dosage: AEROSOL, METERED

Strength	Dosage	Availability
0.044MG/INH	AEROSOL, METERED	Prescription

FLOVENT HFA family patents

16. Kaletra patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309613	ABBVIE	Solid pharmaceutical dosage form	Dec, 2024 (28 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-124)	Apr 27, 2013

Drugs and Companies using LOPINAVIR; RITONAVIR ingredient

Market Authorisation Date: 09 November, 2007

Treatment: Treatment of hiv-infection in combination with other antiretroviral agents

Dosage: TABLET

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mg/25 mg and 200 mg/50 mg	23 Dec, 2008	1		10 Nov, 2020	Extinguished
80 mg/20 mg per mL	19 Jun, 2014	1	27 Dec, 2016	28 Nov, 2021	Deferred

Strength	Dosage	Availability
100MG;25MG	TABLET	Prescription
200MG;50MG	TABLET	Prescription

KALETRA family patents

17. Naloxone Hydrochloride (autoinjector) patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690	KALEO INC	Devices, systems and methods for medicament delivery	Jan, 2025 (6 days ago)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: NA

Dosage: SOLUTION

Strength	Dosage	Availability
10MG/0.4ML (10MG/0.4ML)	SOLUTION	Discontinued

NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents

18. Testim patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320968	ENDO OPERATIONS	Pharmaceutical composition	Jan, 2025 (3 days ago)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 31 October, 2002

Treatment: Method for administration of testosterone

Dosage: GEL

Strength	Dosage	Availability
50MG/5GM PACKET	GEL	Prescription

TESTIM family patents

19. Trilipix patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7259186	ABBVIE	Salts of fenofibric acid and pharmaceutical formulations thereof	Jan, 2025 (14 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 15, 2011

Drugs and Companies using CHOLINE FENOFIBRATE ingredient

Market Authorisation Date: 15 December, 2008

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE

Strength	Dosage	Availability
EQ 45MG FENOFIBRIC ACID	CAPSULE, DELAYED RELEASE	Prescription
EQ 135MG FENOFIBRIC ACID	CAPSULE, DELAYED RELEASE	Prescription

TRILIPIX family patents

20. Twinject 0.15 patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297136	IMPAX	Medicine injection devices and methods	Jan, 2025 (3 days ago)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 25 November, 2009

Treatment: NA

Dosage: INJECTABLE

TWINJECT 0.15 family patents

21. Twinject 0.3 patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297136	IMPAX	Medicine injection devices and methods	Jan, 2025 (3 days ago)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 25 November, 2009

Treatment: NA

Dosage: INJECTABLE

TWINJECT 0.3 family patents

22. Uzedy patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439905	TEVA	Risperidone-containing implants and methods of use thereof	Jan, 2025 (9 days ago)
US8802127	TEVA	Risperidone-containing PLA:PGA implants and methods of use thereof	Jan, 2025 (9 days ago)
US9925268	TEVA	Drug-containing implants and methods of use thereof	Jan, 2025 (9 days ago)
US10736965	TEVA	Risperidone biodegradable implant	Jan, 2025 (9 days ago)
US9895447	TEVA	Drug-containing PLA implants and methods of use thereof	Jan, 2025 (9 days ago)
US9717799	TEVA	Drug-containing implants and methods of use thereof	Jan, 2025 (9 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Apr 28, 2026

Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 28 April, 2023

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE

UZEDY family patents

23. Ventolin Hfa patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444	GLAXOSMITHKLINE	Actuation indicator for a dispensing device	Jan, 2025 (17 days ago)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 19 April, 2001

Treatment: NA

Dosage: AEROSOL, METERED

VENTOLIN HFA family patents

24. Victrelis patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43298	MERCK SHARP DOHME	Peptides as NS3-serine protease inhibitors of hepatitis C virus	Dec, 2024 (30 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Feb 13, 2016
M(M-126)	Feb 27, 2016
New Chemical Entity Exclusivity(NCE)	May 13, 2016

Drugs and Companies using BOCEPREVIR ingredient

NCE-1 date: 14 May, 2015

Market Authorisation Date: 13 May, 2011

Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease

Dosage: CAPSULE

VICTRELIS family patents

25. Vyzulta patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7910767	BAUSCH AND LOMB	Prostaglandin derivatives	Jan, 2025 (16 days ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7629345	BAUSCH AND LOMB	Prostaglandin derivatives	Jan, 2025 (16 days ago)

Drugs and Companies using LATANOPROSTENE BUNOD ingredient

Market Authorisation Date: 02 November, 2017

Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS

VYZULTA family patents

26. Winlevi patent expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143240	SUN PHARM	17α, 21-dihydroxypregnene esters as antiandrogenic agents	Jan, 2025 (9 days ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Aug 26, 2025

Drugs and Companies using CLASCOTERONE ingredient

NCE-1 date: 26 August, 2024

Market Authorisation Date: 26 August, 2020

Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate

Dosage: CREAM

Strength	Dosage	Availability
75MG/0.21ML (75MG/0.21ML)	SUSPENSION, EXTENDED RELEASE	Prescription
200MG/0.56ML (200MG/0.56ML)	SUSPENSION, EXTENDED RELEASE	Prescription
50MG/0.14ML (50MG/0.14ML)	SUSPENSION, EXTENDED RELEASE	Prescription
250MG/0.7ML (250MG/0.7ML)	SUSPENSION, EXTENDED RELEASE	Prescription
100MG/0.28ML (100MG/0.28ML)	SUSPENSION, EXTENDED RELEASE	Prescription
150MG/0.42ML (150MG/0.42ML)	SUSPENSION, EXTENDED RELEASE	Prescription
125MG/0.35ML (125MG/0.35ML)	SUSPENSION, EXTENDED RELEASE	Prescription

Pharsight

Pharsight

Recently Expired Drugs

1. Abilify patent expiration

ABILIFY family patents

2. Adrenaclick patent expiration

ADRENACLICK family patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years. Get the exclusive patent insights now. Don't be the last to know. Download Report 3. Advair Hfa patent expiration

ADVAIR HFA family patents

4. Ampyra patent expiration

AMPYRA family patents

5. Auvi-q patent expiration

AUVI-Q family patents

6. Bepreve patent expiration

BEPREVE family patents

7. Duvyzat patent expiration

DUVYZAT family patents

8. Edarbi patent expiration

EDARBI family patents

9. Edarbyclor patent expiration

EDARBYCLOR family patents

10. Entresto patent expiration

ENTRESTO family patents

11. Entresto Sprinkle patent expiration

ENTRESTO SPRINKLE family patents

12. Evzio patent expiration

EVZIO family patents

13. Evzio (autoinjector) patent expiration

EVZIO (AUTOINJECTOR) family patents

14. Fentora patent expiration

FENTORA family patents

15. Flovent Hfa patent expiration

FLOVENT HFA family patents

16. Kaletra patent expiration

KALETRA family patents

17. Naloxone Hydrochloride (autoinjector) patent expiration

NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents

18. Testim patent expiration

TESTIM family patents

19. Trilipix patent expiration

TRILIPIX family patents

20. Twinject 0.15 patent expiration

TWINJECT 0.15 family patents

21. Twinject 0.3 patent expiration

TWINJECT 0.3 family patents

22. Uzedy patent expiration

UZEDY family patents

23. Ventolin Hfa patent expiration

VENTOLIN HFA family patents

24. Victrelis patent expiration

VICTRELIS family patents

25. Vyzulta patent expiration

VYZULTA family patents

26. Winlevi patent expiration

WINLEVI family patents

Related content

Have Questions?

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Advair Hfa patent expiration